Blake Aftab
Known title: Chief Scientific OfficerCIK: 0001886986
Associated companies
Transaction History
| ACET | ▼ Sell | Tax Withholding | 535 | $5K | 1/24/2026 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 6,270 | $6K | 1/24/2025 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 3,565 | $9K | 1/24/2024 | View on chart |
| ACET | ▲ Buy | Grant | 19,700 | $0 | 1/24/2024 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 7,933 | $11K | 10/12/2023 | View on chart |
| ACET | ▲ Buy | Grant | 26,100 | $0 | 1/24/2023 | View on chart |
| ACET | ▼ Sell | Open Market | 6,967 | $146K | 11/10/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 8,067 | $131K | 10/19/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 7,933 | $126K | 10/13/2022 | View on chart |
| ACET | ▲ Buy | Option Exercise | 3,388 | $25K | 10/12/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 1,646 | $25K | 10/12/2022 | View on chart |
| ACET | ▲ Buy | Grant | 16,000 | $0 | 8/4/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 5,533 | $101K | 8/4/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 6,968 | $125K | 8/3/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 6,968 | $116K | 8/1/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 1,363 | $20K | 7/5/2022 | View on chart |
| ACET | ▲ Buy | Grant | 16,000 | $0 | 2/14/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 5,533 | $79K | 2/14/2022 | View on chart |
| ACET | ▲ Buy | Grant | 16,000 | $0 | 1/28/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 5,564 | $65K | 1/28/2022 | View on chart |
| ACET | ▲ Buy | Grant | 80,000 | $0 | 10/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target
Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.